Impact of recombinant human growth hormone treatment in children with growth disorders secondary to nephrotic syndrome
Journal of Nephrology · 2026
DOI: 10.1093/joneph/aajag098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nephrology, 2026. Verfasst von Fazhan Zhong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510120, China. Hauptthemen laut MEDLINE: Nephrotic Syndrome, Human Growth Hormone, Growth Disorders, Body Height. Die Arbeit nennt 28 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Patients with nephrotic syndrome (NS) treated with glucocorticoids often suffer from growth disorders. This study aimed to explore the impact of recombinant human growth hormone treatment in children with growth disorders secondary to NS.
Methods
This retrospective study enrolled patients with NS treated at Guangzhou Women and Children's Medical Center between May 2015 and November 2023. Patients were divided into the recombinant human growth hormone group and the conventional group. The primary outcome was height increment. Secondary outcomes included height standard deviation score, predicted adult height standard deviation score, and height velocity.
Results
Among 129 enrolled children (89 in the recombinant human growth hormone group, 40 in the conventional group), the recombinant human growth hormone group showed significantly greater height increments at 6 months (4.80 ± 1.42 vs. 2.02 ± 0.91 cm), 12 months (9.07 ± 2.46 vs. 4.39 ± 1.73 cm), and 24 months (15.34 ± 5.20 vs. 7.88 ± 3.43 cm; all P < .001). Similarly, height standard deviation score and predicted adult height standard deviation score improvements were significantly greater in the recombinant human growth hormone group at all time points (all P < .001). Height velocity was also higher in the recombinant human growth hormone group at 6 and 12 months (both P < .001). These associations remained significant after multivariate adjustment. No significant differences in glucocorticoid exposure during follow-up were observed between groups. Multivariate analysis at 12 months indicated that cumulative glucocorticoid dosage was negatively associated with height standard deviation score (β=−.0022, 95% CI: −0.0041, −0.0004; P = .020) and predicted adult height (β=−.0148, 95% CI: −0.0288, −0.0008; P = .038).
Conclusion
The results suggested that recombinant human growth hormone treatment in children with NS significantly improved height, height standard deviation score, predicted adult height standard deviation score, and height velocities, compared with conventional treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510120, China.
- Pediatric Emergency Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510120, China.
ORCID-Profile: Xia Gao
Zitieren
APA
Zhong, F., Fan, X., Zhang, M., Yang, H., Deng, H., Gao, Y., Li, P., & Gao, X. (2026). Impact of recombinant human growth hormone treatment in children with growth disorders secondary to nephrotic syndrome. Journal of Nephrology. https://doi.org/10.1093/joneph/aajag098
Vancouver
Zhong F, Fan X, Zhang M, Yang H, Deng H, Gao Y, et al. Impact of recombinant human growth hormone treatment in children with growth disorders secondary to nephrotic syndrome. Journal of Nephrology. 2026. doi:10.1093/joneph/aajag098
BibTeX
@article{Zhong2026,
author = {Zhong, Fazhan and Fan, Xiaowei and Zhang, Miao and Yang, Huabin and Deng, Huiying and Gao, Yan and Li, Peiqing and Gao, Xia},
title = {Impact of recombinant human growth hormone treatment in children with growth disorders secondary to nephrotic syndrome},
journal = {Journal of Nephrology},
year = {2026},
doi = {10.1093/joneph/aajag098}
}
EUVIMED